- Home
- USA vs CRVS Comparison
USA vs CRVS Comparison
Compare USA & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | USA | CRVS |
|---|---|---|
| Founded | 1986 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | USA | CRVS |
|---|---|---|
| Price | $5.96 | $18.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $28.00 |
| AVG Volume (30 Days) | 880.5K | ★ 7.7M |
| Earning Date | 01-01-0001 | 03-24-2026 |
| Dividend Yield | ★ 9.66% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.62 | $2.54 |
| 52 Week High | $7.09 | $26.95 |
Technical Indicators
Market Signals| Indicator | USA | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 38.49 | 57.79 |
| Support Level | $5.93 | $18.50 |
| Resistance Level | $6.08 | $21.57 |
| Average True Range (ATR) | 0.07 | 1.69 |
| MACD | -0.01 | -0.59 |
| Stochastic Oscillator | 23.08 | 10.48 |
Price Performance
Historical ComparisonAbout USA Liberty All-Star Equity Fund
Liberty All Star Equity Fund is a multi-managed fund. Its objective is to provide a high level of current income and long-term capital appreciation through investing principally in a diversified portfolio of equity securities. The fund invests in various sectors, including financials, information technology, healthcare, consumer discretionary, consumer staples, industrials, energy, materials, real estate, utilities, telecommunication, and other services.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).